Amendments to the Claims:

1-118. (canceled).

119. (previously presented) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314);

(b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314);

(d) the nucleic acid sequence of (SEQ ID NO:313);

(e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203128;

wherein said polypeptide encoded by said nucleic acid is an immunostimulant.

120. (previously presented) An isolated nucleic acid of Claim 119 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314);

(b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314);

(d) the nucleic acid sequence of (SEQ ID NO:313);

(e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203128;

wherein said polypeptide encoded by said nucleic acid is an immunostimulant.

121. (previously presented) An isolated nucleic acid of Claim 119 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314);

(b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314);

(d) the nucleic acid sequence of (SEQ ID NO:313);

(e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203128;

wherein said polypeptide encoded by said nucleic acid is an immunostimulant.

122. (previously presented) An isolated nucleic acid of Claim 119 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314);

(b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314);

(d) the nucleic acid sequence of (SEQ ID NO:313);

(e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203128;

wherein said polypeptide encoded by said nucleic acid is an immunostimulant.

123. (previously presented) An isolated nucleic acid of Claim 119 having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314);

(b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314);

(d) the nucleic acid sequence of (SEQ ID NO:313);

(e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203128;

wherein said polypeptide encoded by said nucleic acid is an immunostimulant.

124. (previously presented) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314);

(b) a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314);

(d) the nucleic acid sequence of (SEQ ID NO:313);

(e) the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 203128;

wherein said polypeptide encoded by said nucleic acid is an immunostimulant.

125. (previously presented) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314).

126. (previously presented) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide.

127. (previously presented) The isolated nucleic acid of Claim 124 comprising the nucleic acid sequence encoding the extracellular domain of the polypeptide of (SEQ ID NO:314), lacking its associated signal peptide.

128. (canceled).

129. (previously presented) The isolated nucleic acid of Claim 124 comprising the nucleic acid sequence of (SEQ ID NO:313).

130. (previously presented) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the nucleic acid sequence of (SEQ ID NO:313).

131. (previously presented) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 203128.

132. (canceled).

133 (canceled).

134. (canceled).

135. (previously presented) A vector comprising the nucleic acid of Claim 124

136. (previously presented) The vector of Claim 135, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

137. (previously presented) A host cell comprising the vector of Claim 135.

138. (previously presented) The host cell of Claim 137, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.